Jun Liu

Jun Liu

Auto-generated profile, based on publicly available information

Jun Liu

State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2025 in Cancer Research
Verified
Journal Article
Closed access
JZJiarong Zhan
Jiarong Zhan
MLMengqing Li
Mengqing Li
LLLei Li
Lei Li
TZTing-Ting Zeng
Ting-Ting Zeng
JLJun Liu
Jun Liu
YZYing-Hui Zhu
Ying-Hui Zhu
Cancer-associated fibroblasts (CAF) are pivotal constituents of the tumor microenvironment that significantly influence cancer aggressiveness through the secretion of various factors. A more detailed characterization of the specific secretions exclusive to CAFs that drive tumor progression could identify potential targets to perturb this intracellular cross-talk. In this study, we identified latent TGFβ-binding protein 2 (LTBP2) as a unique protein secreted exclusively by esophageal squamous cell carcinoma (ESCC) CAFs that promotes metastasis and chemoresistance. LTBP2 exerted its oncogenic effects by interacting with integrin α6β4, which serves as a functional receptor, and thereby activating Src signaling in ESCC cells. Notably, targeting LTBP2 with specific antagonistic antibodies markedly increased the susceptibility of ESCC cells to chemotherapeutic agents. These findings highlight the pivotal role of LTBP2 as a crucial mediator of CAF-induced cancer cell aggression and introduce it as a promising target to enhance chemotherapeutic efficacy in ESCC. Significance: CAF-secreted LTBP2 binds integrin α6β4 and activates Src signaling to drive metastasis and chemoresistance in esophageal cancer, highlighting LTBP2 as a key regulator of CAF-mediated tumor progression that can be therapeutically targeted.

2 July 2025
Verified
Other
Open access
JZJiarong Zhan
Jiarong Zhan
MLMengqing Li
Mengqing Li
LLLei Li
Lei Li
TZTing-Ting Zeng
Ting-Ting Zeng
JLJun Liu
Jun Liu
YZYing-Hui Zhu
Ying-Hui Zhu
Cancer-associated fibroblasts (CAF) are pivotal constituents of the tumor microenvironment that significantly influence cancer aggressiveness through the secretion of various factors. A more detailed characterization of the specific secretions exclusive to CAFs that drive tumor progression could identify potential targets to perturb this intracellular cross-talk. In this study, we identified latent TGFβ-binding protein 2 (LTBP2) as a unique protein secreted exclusively by esophageal squamous cell carcinoma (ESCC) CAFs that promotes metastasis and chemoresistance. LTBP2 exerted its oncogenic effects by interacting with integrin α6β4, which serves as a functional receptor, and thereby activating Src signaling in ESCC cells. Notably, targeting LTBP2 with specific antagonistic antibodies markedly increased the susceptibility of ESCC cells to chemotherapeutic agents. These findings highlight the pivotal role of LTBP2 as a crucial mediator of CAF-induced cancer cell aggression and introduce it as a promising target to enhance chemotherapeutic efficacy in ESCC.Significance:CAF-secreted LTBP2 binds integrin α6β4 and activates Src signaling to drive metastasis and chemoresistance in esophageal cancer, highlighting LTBP2 as a key regulator of CAF-mediated tumor progression that can be therapeutically targeted.

2 July 2025
Verified
Other
Open access
PDF file
JZJiarong Zhan
Jiarong Zhan
MLMengqing Li
Mengqing Li
LLLei Li
Lei Li
TZTing-Ting Zeng
Ting-Ting Zeng
JLJun Liu
Jun Liu
YZYing-Hui Zhu
Ying-Hui Zhu
LTBP2 enhances proliferation and resistance to paclitaxel in ESCC cells

2 July 2025
Verified
Other
Open access
PDF file
JZJiarong Zhan
Jiarong Zhan
MLMengqing Li
Mengqing Li
LLLei Li
Lei Li
TZTing-Ting Zeng
Ting-Ting Zeng
JLJun Liu
Jun Liu
YZYing-Hui Zhu
Ying-Hui Zhu
YAP1-TEAD1 activates LTBP2 transcription in CAFs

2 July 2025
Verified
Other
Open access
PDF file
JZJiarong Zhan
Jiarong Zhan
MLMengqing Li
Mengqing Li
LLLei Li
Lei Li
TZTing-Ting Zeng
Ting-Ting Zeng
JLJun Liu
Jun Liu
YZYing-Hui Zhu
Ying-Hui Zhu
Dose-dependent effects of LTBP2 on migration and chemoresistance in ESCC cells

2 July 2025
Verified
Other
Open access
PDF file
JZJiarong Zhan
Jiarong Zhan
MLMengqing Li
Mengqing Li
LLLei Li
Lei Li
TZTing-Ting Zeng
Ting-Ting Zeng
JLJun Liu
Jun Liu
YZYing-Hui Zhu
Ying-Hui Zhu
Anti–integrin α6 or anti–integrin β4 antibody treatment mitigates ESCC cell migration and enhances chemotherapy sensitivity